---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-033675"
form_type: "8-K"
ticker: "STSS"
cik: "0001737995"
company_name: "Sharps Technology Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:44:47.117791+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sharps Tech signs $50M asset purchase agreement for InjectEZ facility and $400M+ supply deal with Nephron

## Summary
- Acquisition of InjectEZ syringe facility for $40.4M cash, $10M subordinated note, and warrants for 4% of fully diluted shares at $1.56.
- 10-year purchase agreement with Nephron for minimum $400M in copolymer syringes; initial $30M PO at closing, $45M+ per year from 2025.
- Signed term sheet for up to $75M debt financing from a middle-market lender to fund the acquisition and operations.
- Closing expected within 60 days, subject to customary conditions and securing committed financing; facility lease at $40,550/month.
- Deal transforms Sharps into commercial manufacturer with copolymer prefillable syringe capacity, targeting Q1 2024 deliveries.

## SEC filing metadata
- accession: 0001493152-23-033675
- form_type: 8-K
- ticker: STSS
- cik: 0001737995
- company_name: Sharps Technology Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737995/000149315223033675/0001493152-23-033675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737995/000149315223033675/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-033675
- JSON: https://secwatch.observer/filing/0001493152-23-033675.json
- Plain text: https://secwatch.observer/filing/0001493152-23-033675.txt

## Key facts
- Material Agreements
  Sharps Technology Inc. entered into Asset Purchase Agreement with Nephron Pharmaceuticals Corporation and Nephron’s wholly owned subsidiary Inject E-Z, LLC (collectively, “Nephron”) valued at $40,378,594 and the issuance of a five (5) year subordinated promissory note ... in the principal am (effective 2023-09-22).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Nephron Pharmaceuticals Corporation and Nephron’s wholly owned subsidiary Inject E-Z, LLC (collectively, “Nephron”)
  - Value: $40,378,594 and the issuance of a five (5) year subordinated promissory note ... in the principal am
  - Effective: 2023-09-22
  source text: On September 22, 2023, Sharps Technology, Inc. (and its wholly-owned subsidiary Sharps Technology Acquisition Corp., collectively, (the “Company”) entered into a series of agreements with Nephron Pharmaceuticals Corporation and Nephron’s wholly owned subsidiary Inject E-Z, LLC. (collectively, “Nephron”). The Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) to purchase certain equipment and leasehold improvements at Nephron’s facility (the “Facility”) in West Columbia, South Carolina. The Asset Purchase Agreement provides for a cash purchase price of $40,378,594 and the issuance of a five (5) year subordinated promissory note (the “Nephron Note”) to Nephron in the principal amount of $10.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737995/000149315223033675/0001493152-23-033675-index.htm
- Material Agreements
  Sharps Technology Inc. entered into Purchase Agreement with Nephron valued at minimum aggregate of at least $400.0 million of syringes over the term of the Purchase Agreement (effective 2023-09-19).
  - Action: entry
  - Agreement: supply
  - Counterparty: Nephron
  - Value: minimum aggregate of at least $400.0 million of syringes over the term of the Purchase Agreement
  - Effective: 2023-09-19
  source text: In conjunction with the execution of the Asset Purchase Agreement, on September 19, 2023, the Company entered into a ten-year Purchase Agreement with Nephron whereby Nephron agreed to utilize the Company as its exclusive pre-filled copolymer syringe manufacturer and to purchase a minimum aggregate of at least $400.0 million of syringes over the term of the Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737995/000149315223033675/0001493152-23-033675-index.htm
- Material Agreements
  Sharps Technology Inc. entered into Lease with Nephron valued at monthly rental fee of $40,550.
  - Action: entry
  - Agreement: lease
  - Counterparty: Nephron
  - Value: monthly rental fee of $40,550
  source text: At the Closing, the Company will enter into a 10 year lease for the Facility in which the Assets are located and will be operated by the Company. The lease provides for four successive five year options, with a right to purchase the Facility, which lease will be effective upon Closing (the “Lease”). The Lease provides for a monthly rental fee of $40,550, subject to increase after 5 years based on CPI adjustments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737995/000149315223033675/0001493152-23-033675-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.